respiratori
infect
children
diagnost
remain
neg
suggest
patient
might
infect
yet
unknown
pathogen
viru
discoveri
cdnaaflp
vidisca
viru
discoveri
method
base
recognit
restrict
enzym
cleavag
site
ligat
adaptor
subsequ
amplif
pcr
howev
direct
discoveri
unknown
pathogen
nasopharyng
swab
difficult
due
high
concentr
ribosom
rna
rrna
act
competitor
current
studi
optim
vidisca
adjust
revers
transcript
enzym
decreas
rrna
amplif
revers
transcript
use
hexam
oligonucleotid
anneal
rrna
residu
cdna
synthesi
rrna
templat
reduc
oligonucleotid
anneal
rrna
extend
due
modif
reduct
rrna
amplif
establish
improv
vidisca
sensit
obtain
high
throughput
sequenc
eighteen
nasopharyng
swab
analys
contain
known
respiratori
virus
could
identifi
proper
viru
major
sampl
test
median
load
posit
sampl
viral
genom
copiesml
rang
result
show
optim
vidisca
subsequ
highthroughputsequenc
enhanc
sensit
drastic
provid
opportun
perform
viru
discoveri
directli
patient
materi
respiratori
tract
infect
common
caus
hospit
children
age
year
hospit
infecti
agent
identifi
suspect
viral
infect
involv
case
yet
unknown
viru
might
caus
respiratori
ill
last
decad
sever
viral
discoveri
method
develop
detect
virus
without
knowledg
genom
sequenc
previous
use
viru
discoveri
cdnaaflp
vidisca
discov
human
coronaviru
first
describ
human
parechoviru
type
netherland
use
techniqu
vidisca
assay
viral
genom
revers
transcrib
doubl
strand
dna
digest
restrict
enzym
enzym
digest
short
nucleotid
recognit
sequenc
present
virtual
virus
ligat
adaptor
digest
fragment
pcr
amplifi
adaptorspecif
primer
assay
userfriendli
howev
sensit
assay
low
least
genom
copiesml
viru
background
low
competitor
rnadna
need
condit
gener
met
viru
cultur
supernat
use
clinic
respiratori
sampl
like
nasopharyng
swab
univers
transport
medium
utm
variou
amount
competitor
rnadna
disrupt
cell
bacteria
present
ribosom
rna
total
cellular
rna
one
biggest
problem
due
high
copi
number
stabil
within
ribosom
particular
rna
virus
difficult
discov
sinc
case
revers
transcript
need
enabl
rrna
act
competit
nucleic
acid
sequenc
one
research
group
address
problem
compet
rrna
endoh
et
al
show
revers
transcript
hexam
anneal
rrna
decreas
amount
background
amplif
enhanc
sensit
viru
discoveri
assay
evalu
benefit
nonrrnahexam
vidisca
furthermor
evalu
whether
choic
restrict
enzym
decreas
rrna
amplif
final
specif
block
rrna
revers
transcript
rrna
recogn
oligo
contain
modif
extend
inhibit
cdna
synthesi
target
three
step
decreas
effect
inhibitor
rrna
present
paper
furthermor
monitor
perform
optim
amplif
high
throughput
sequenc
set
combin
vidisca
roch
gs
flx
titanium
sequenc
respiratori
sampl
contain
nonvir
nucleic
acid
interfer
viru
discoveri
techniqu
like
vidisca
rel
easi
decreas
influenc
background
bacteri
human
dna
mrna
centrifug
dnasernas
treatment
ribosom
rna
rrna
difficult
elimin
ribosom
protein
protect
rrna
insid
ribosom
instead
degrad
compet
rrna
option
adjust
amplif
procedur
vidisca
rrna
amplif
decreas
method
adjust
sever
level
nonrrnaannealingprim
use
revers
transcript
choic
certain
restrict
enzym
made
diminish
chanc
rrna
digest
subsequ
amplif
rrnablock
oligo
use
revers
transcript
halt
cdna
synthesi
rrna
templat
nonrrnahexam
revers
transcript
reaction
endoh
colleagu
design
mix
hexam
hardli
target
rrna
amplifi
known
virus
rtpcr
nonrrnahexam
test
vidisca
use
dilut
rang
human
echoviru
cultur
supernat
copiesml
viru
harvest
establish
contain
competitor
rrna
cdna
produc
either
normal
hexam
contain
variant
nonrrnahexam
viral
sequenc
could
detect
sampl
concentr
viral
genom
rna
copiesml
see
figur
case
nonrrnahexam
use
rt
reaction
wherea
sampl
treat
normal
random
hexam
posit
highest
concentr
copiesml
moreov
viral
fragment
amplifi
nonrrnahexam
amplif
wherea
viral
fragment
amplifi
standard
procedur
figur
figur
show
sensit
caus
reduc
competitor
rrna
amplif
sinc
pcr
fragment
origin
rrna
notabl
reduc
arrow
figur
quantifi
inhibit
rrna
amplif
perform
variou
realtim
pcr
target
cdna
rrna
rrna
use
nasopharyng
swab
ii
input
sampl
contain
high
concentr
rrna
sampl
revers
transcrib
either
complet
set
hexam
nonrrnahexam
nonrrnahexam
substanti
lower
amount
rrnaderiv
cdna
gener
averag
log
decreas
compar
sampl
treat
random
hexam
see
tabl
observ
decreas
cdna
synthesi
rrna
rrna
consider
ct
log
howev
strong
decreas
region
rrna
almost
log
decreas
tabl
inspect
nonrrnahexam
reveal
phenomenon
explain
residu
prime
nonrrnahexam
although
primer
design
anneal
hardli
rrna
perfectli
match
human
rrna
especi
region
posit
rrna
region
till
posit
howev
region
show
strong
decreas
rrna
cdna
synthesi
rrna
rrna
nonrrnahexam
anneal
close
vicin
posit
respect
one
might
suggest
expel
hexam
anneal
abovement
locat
enhanc
benefit
nonrrna
cdna
synthesi
howev
endoh
et
al
design
nonribosom
hexam
amplif
virus
hamper
therefor
recommend
use
endohdesign
nonrrna
hexam
check
whether
viral
amplif
hamper
use
nonrrnahexam
cdna
synthesi
perform
realtim
pcr
cdna
echoviru
human
coxsackieviru
viru
cultur
supernat
case
cdna
synthesi
nonrrnahexam
occur
effici
normal
hexam
differ
viru
specif
real
time
pcr
note
tabl
demonstr
endoh
et
al
sarscov
bovin
control
virus
nonrrna
target
restrict
enzym
digest
origin
vidsica
method
describ
base
amplif
digest
restrict
enzym
msei
investig
human
rrna
reveal
rrna
contain
high
number
recognit
site
see
tabl
rel
low
frequenc
msei
restrict
site
high
frequenc
digest
rrna
gener
massiv
amount
small
digest
fragment
like
interfer
vidiscalig
vidisca
also
perform
one
restrict
enzym
adapt
need
addit
differ
adaptor
ligat
msei
digest
fragment
check
hypothesi
digest
coxsackieviru
cultur
supernat
msei
comparison
combin
evalu
effici
viral
genom
amplif
singl
pcr
observ
strongli
reduc
background
amplif
case
msei
use
vidisca
figur
dot
indic
viral
fragment
rrnablock
oligo
revers
transcript
reaction
improv
sensit
vidisca
even
design
oligonucleotid
block
amplif
ribosom
rna
oligonucleotid
design
anneal
specif
rrna
contain
dideoxi
amino
modif
inhibit
elong
thu
amplif
rrnaderiv
cdna
call
rrnablock
oligo
design
preval
rrna
sequenc
retriev
vidisca
experi
nasopharyng
swab
test
inhibitori
capac
block
oligo
perform
vidisca
nasopharyng
sampl
input
block
oligo
ad
revers
transcriptas
reaction
inhibit
observ
block
oligo
ad
indic
arrow
figur
sequenc
inhibit
pcr
product
confirm
deriv
rrna
indic
block
oligo
reduc
amplif
rrna
addit
perform
realtim
rtpcr
target
rrna
input
nasopharyng
sampl
use
sampl
use
nonrrna
anneal
hexam
monitor
cdna
synthesi
via
real
time
pcr
region
rrna
region
rrna
choic
region
monitor
rrnacdna
revers
trancript
effici
base
vidisca
fragment
know
gener
vidisca
amplif
three
region
target
rrnablock
oligo
averag
reduct
rrna
amplif
notic
region
target
rrnablock
oligo
see
tabl
note
reduct
visibl
fragment
target
blocker
rrna
expect
one
except
observ
howev
sampl
ii
diminish
signal
observ
rrna
sampl
extrem
high
concentr
rrna
ct
valu
thu
investig
whether
rrnablock
oligo
would
work
better
sampl
higher
concentr
blocker
use
inde
mm
mm
decreas
signal
note
decreas
decreas
respect
indic
sampl
concentr
mm
might
suboptim
howev
diminish
chanc
unspecif
block
viral
rna
prefer
mm
concentr
rrnablock
oligo
concentr
observ
decreas
cdna
synthesi
coxsackieviru
measur
realtim
rtpcr
tabl
figur
shown
sensit
vidisca
reach
viral
genom
copiesml
although
improv
detect
limit
might
low
detect
virus
directli
clinic
sampl
concentr
respiratori
virus
nasopharyng
swab
main
copiesml
assum
yet
unknown
viru
present
similar
concentr
thu
addit
improv
vidiscasensit
need
high
throughput
sequenc
rel
new
method
allow
million
nucleotid
sequenc
one
run
pyrosequenc
one
devic
flxtitanium
system
roch
gener
dna
fragment
approxim
nucleotid
per
run
gener
thousand
clonal
amplifi
sequenc
singl
sampl
viral
minor
detect
vidisca
techniqu
easili
adapt
sequenc
method
anchor
ligat
digest
fragment
design
contain
b
primer
sequenc
need
clonal
amplif
emuls
pcr
use
input
flx
sequenc
howev
becom
costeffect
case
thousand
sequenc
suffici
viru
detect
one
plate
use
analyz
sampl
roughli
j
per
sampl
view
benefit
strongli
aforement
reduct
rrna
amplif
sinc
fewer
sequenc
need
detect
viral
sequenc
monitor
effici
nasopharyng
swab
contain
known
virus
one
third
picotiterpl
use
check
whether
inde
thousand
sequenc
enough
viru
detect
sampl
select
randomli
larg
sampl
set
collect
grace
studi
larg
eu
financ
studi
acut
cough
antibiot
use
adult
sampl
assign
posit
via
specif
diagnost
pcr
suppli
us
doubl
blind
ensur
unbias
sequenc
analys
sampl
process
identifi
sequenc
allow
pool
emuls
pcr
product
visual
agaros
gel
fragment
cut
gel
differ
size
region
bp
sampl
run
region
region
picotiterpl
titanium
system
per
region
mid
tag
sampl
pool
process
accord
small
volum
emuls
pcr
total
read
gener
viral
sampl
viral
sequenc
could
identifi
match
respiratori
viru
found
diagnost
pcr
tabl
frequenc
viral
sequenc
per
sampl
rang
tabl
median
viral
load
posit
sampl
viral
genom
copi
ml
rang
genom
copiesml
detect
correl
input
viral
load
sinc
low
load
sampl
remain
neg
median
viral
genom
concentr
vidiscaneg
sampl
rang
posit
sampl
larg
genom
coverag
observ
see
tabl
nowaday
molecular
techniqu
becom
standard
discoveri
new
virus
method
use
conserv
region
univers
primer
design
base
known
viral
genom
method
applic
specif
viru
famili
use
virus
furthermor
yet
unknown
virus
could
divers
therefor
remain
neg
kind
detect
techniqu
sequenc
independ
amplif
method
vidisca
randompcr
identifi
viral
sequenc
without
prior
knowledg
viral
genom
unfortun
detect
unknown
viral
pathogen
respiratori
clinic
materi
difficult
sequenc
independ
viru
discoveri
method
low
viral
load
high
background
nucleic
acid
sampl
last
year
sequenc
independ
viru
discoveri
techniqu
mostli
use
viru
cultur
supernat
contain
high
concentr
viral
genom
discov
previous
unknown
dna
virus
far
studi
abl
identifi
novel
human
respiratori
rna
virus
sequenc
independ
amplif
techniqu
thu
sequenc
independ
amplif
techniqu
like
vidisca
optim
allow
discoveri
without
requir
cultur
amplif
step
current
studi
increas
sensit
vidisca
reduc
background
rrna
amplif
increas
number
sequenc
obtain
sampl
manag
unfavor
rrna
amplif
adjust
revers
transcript
step
util
primer
cdna
synthesi
poorli
recogn
rrna
combin
addit
oligo
halt
cdna
synthesi
rrna
templat
success
decreas
interf
background
amplif
addit
use
singl
restrict
enzym
low
number
recognit
site
rrna
provid
reduct
useless
interf
amplif
thu
step
increas
ratio
viral
genom
versu
rrna
amplif
benefit
shown
vidiscahigh
throughput
sequenc
clinic
sampl
contain
known
virus
major
clinic
sampl
viru
easili
identifi
two
case
even
input
genom
copi
adenoviru
influenza
viru
could
detect
ideal
oldprotocol
two
restrict
enzym
random
hexam
rrnablock
oligo
compar
optim
howev
comparison
regrett
possibl
due
limit
respiratori
clinic
specimen
use
thu
reli
reconstruct
monitor
perform
normal
vidisca
mention
use
one
restrict
enzym
msei
diminish
background
rrna
amplif
one
addit
advantag
singl
restrict
enzym
usag
tradit
vidisca
two
restrict
enzym
combin
msei
fragment
one
restrict
site
site
site
amplifi
ligat
vidisca
amplif
restrict
case
one
two
enzym
recognit
site
posit
site
optim
far
close
use
one
restrict
enzym
larg
part
genom
would
divid
amplifi
product
provid
fragment
size
bp
case
singl
restrict
enzym
digest
anchor
potenti
ligat
msei
gener
sticki
end
ab
ba
contain
fragment
use
sequenc
might
give
suggest
vidisca
product
ineffect
contain
adaptor
aa
bb
howev
fragment
contain
differ
primer
preferenti
amplifi
pcr
sinc
aa
bb
fragment
disadvantag
end
anneal
interfer
primer
anneal
definit
observ
higher
chanc
amplif
sever
genom
segment
one
restrict
site
use
remark
high
genom
coverag
note
sever
sampl
reach
sampl
contain
rsv
coverag
could
never
achiev
case
two
restrict
enzym
use
amplif
group
use
high
throughput
sequenc
viru
discoveri
well
one
paper
viral
commun
antarct
lake
describ
lopezbueno
et
al
collect
water
spring
late
summer
fresh
water
lake
limnopolar
lake
antarctica
use
high
throughput
sequenc
studi
viral
commun
locat
hardli
visit
larger
eukaryot
first
time
larg
amount
sequenc
data
retriev
isol
place
led
identif
least
viral
famili
two
claim
repres
new
famili
result
show
enorm
possibl
viru
discoveri
high
throughput
sequenc
author
also
address
larg
amount
unknown
sequenc
present
data
set
also
observ
presenc
unknown
sequenc
within
data
set
could
sequenc
deriv
yet
unknown
virus
could
sequenc
part
genom
sequenc
known
organ
eg
bacterium
complet
genom
sequenc
present
genbank
databas
thu
care
taken
assign
sequenc
potenti
viral
sinc
mani
organ
fulli
sequenc
sever
advantag
high
throughput
sequenc
comparison
bigdy
termin
sequenc
first
high
throughput
sequenc
pool
sampl
carri
recognit
sequenc
vidisca
cost
per
sampl
reduc
sinc
select
vidiscapcr
metaphor
agaros
gel
visual
purif
fragment
gel
ta
clone
coloni
pcr
subsequ
bigdy
sequenc
omit
secondli
amount
sequenc
data
receiv
singl
sampl
higher
achiev
standard
vidsca
thu
increas
chanc
identifi
unknown
viru
method
open
new
opportun
viru
discoveri
respiratori
sampl
undiagnos
respiratori
infect
also
diseas
amyotroph
later
sclerosi
al
kawasaki
diseas
kd
multipl
sclerosi
ms
syndrom
viral
pathogen
suggest
could
confirm
far
possibl
investig
sampl
patient
unknown
virus
patient
randomli
chosen
larg
european
eufinanc
grace
studi
http
wwwgracelrtiorg
ethic
review
committe
countri
approv
studi
cardiff
echoviru
human
coxsackieviru
human
coxsackieviru
cultur
epitheli
monkey
kidney
cell
line
mem
hanksearl
medium
invitrogen
inactiv
fetal
bovin
serum
fb
cambrex
bio
scienc
media
supplement
penicillin
mgml
streptomycin
mgml
duchefa
biochemi
virus
harvest
day
except
human
coronaviru
harvest
day
grace
studi
larg
eu
financ
studi
acut
cough
antibiot
use
adult
consult
gener
practition
flock
nasopharyng
swab
copan
univers
transport
medium
utm
collect
patient
eighteen
nasopharyng
specimen
randomli
select
doubl
blind
includ
studi
proven
posit
specif
diagnost
pcr
either
human
rhinoviru
hrv
respiratori
syncyti
viru
rsv
human
coronaviru
influenzaviru
influenzaviru
b
parainfluenzaviru
adenoviru
diagnost
respiratori
virus
determin
inhous
multiplex
realtim
pcr
assay
primer
probe
avail
request
viral
load
determin
virusspecif
quant
real
time
pcr
use
standard
curv
base
plasmid
contain
viru
sequenc
interest
detail
avail
request
nucleid
acid
extract
boom
isol
elut
nucleic
acid
perform
steril
h
mm
rrnablock
oligonucleotid
mm
see
revers
transcript
perform
describ
adjust
case
ng
random
hexam
amersham
bioscienc
nonribosom
hexam
use
enteroviru
realtim
pcr
perform
quantifi
effici
echoviru
human
coxsackieviru
human
coxsackieviru
revers
transcript
reaction
wherea
specif
real
time
pcr
perform
quantifi
revers
transcript
effici
ribosom
rna
real
time
pcr
perform
primer
quantifast
sybr
green
pcr
kit
qiagen
realtim
pcr
primerset
addit
run
probe
platinum
quantit
pcr
supermixudg
system
invitrogen
vidisca
vidisca
perform
describ
adapt
short
cell
debri
mitochondria
remov
centrifug
residu
dna
degrad
u
turbo
tm
dnase
ambion
nucleic
acid
isol
perform
describ
boom
et
al
elut
h
without
mm
rrnablock
oligonucleotid
revers
transcript
perform
mg
random
hexam
amersham
bioscienc
mg
nonribosom
hexam
u
moloney
murin
leukemia
viru
revers
transcriptas
enzym
invitrogen
rt
reaction
second
strand
synthesi
perform
u
klenow
frament
exo
westburg
u
rnase
h
amersham
follow
phenol
chloroform
extract
ethanol
precipit
digest
perform
u
new
england
biolab
msei
new
england
biolab
restrict
enzym
msei
new
england
biolab
ligat
mse
hinp
anchor
perform
describ
case
singl
msei
digest
nd
mse
anchor
ad
topb
bottomb
first
round
pcr
amplif
perform
primer
anneal
anchor
cover
cycl
cycl
case
singl
pcr
use
second
pcr
use
enhanc
signal
use
primer
extend
one
nucleotid
either
c
g
total
primer
combin
pcr
fragment
visual
metaphor
agaros
gel
cambrex
fragment
interest
cut
gel
purifi
nucleospinh
extract
ii
machereynagel
clone
use
topo
ta
clone
kit
invitrogen
sequenc
biddy
termin
reagent
appli
biosystem
data
analysi
conduct
codoncod
align
softwar
blast
vidisca
perform
describ
minor
chang
figur
revers
transcript
perform
superscript
ii
u
invitrogen
mixtur
contain
ecoli
ligas
u
invitrogen
anchor
ligat
perform
anchor
base
primer
identifi
sequenc
mid
nt
see
gs
flx
shotgun
dna
librari
prepar
method
manual
anchor
contain
primer
b
total
differ
identifi
sequenc
use
allow
sampl
pool
amplif
singl
pcr
perform
mm
primer
amid
mm
primer
b
follow
thermocycl
profil
cycl
min
cycl
min
cycl
min
sampl
ml
product
load
agaros
gel
size
region
cut
gel
bp
bp
size
region
purifi
nucleospinh
extract
ii
machereynagel
dna
quantifi
quantit
tm
dsdna
assay
kit
qubit
fluoromet
invitrogen
emuls
pcr
perform
accord
supplier
protocol
liba
sv
empcr
kit
gs
flx
titanium
picotiterpl
kit
gs
flx
titanium
xlr
sequenc
kit
roch
emuls
pcr
amplifi
fragment
differ
sampl
sampl
run
region
picotiterpl
titanium
system
per
region
sampl
run
process
accord
emuls
small
volum
pcr
protocol
bead
per
emuls
input
small
volum
emuls
per
region
direct
titrat
protocol
sequenc
read
assembl
use
codoncod
softwar
wwwcodoncodecom
search
viral
sequenc
perform
blast
tool
genbank
